JAHA:血清非酯化脂肪酸与卒中事件的关系

2021-11-12 MedSci原创 MedSci原创

该研究发现总共有2个NEFA亚类和3个单独的NEFA与卒中发生相关。其中,NEFAn-3亚类和二高-γ-亚麻酸来源于饮食,可能是总体卒中风险的潜在生物标志物。

卒中是导致老年人死亡的第五大原因,也是导致严重长期残疾的常见原因。一些前瞻性队列研究报告了总非酯化脂肪酸(NEFA)浓度与卒中事件之间存在显著关联。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员评估了卒中事件与非酯化饱和、单不饱和、多不饱和和反式脂肪酸的血清浓度之间的关联。

心血管健康研究(CHS)中在基线(1996-1997)时没有卒中并且有一个存档的空腹血清样本参与者(N=2028)被纳入本研究。研究人员使用气相色谱法对35种NEFA进行了定量分析。Cox比例风险回归模型用于评估了单个NEFA水平和NEFA的5个亚类(非酯化饱和、单不饱和、omega(n)-6多不饱和、n-3多不饱和和反式脂肪酸)与卒中之间的关联。研究人员通过排除出血性卒中病例(n=45)进行了敏感性分析。

在中位10.5年的随访期间内,共有338例卒中事件发生。NEFA中总n-3(风险比[HR]为0.77[95%CI为0.61-0.97])和总n-6(HR为1.32[95%CI为1.01-1.73])亚类与卒中事件发生分别呈负相关和正相关。在单个NEFA中,二高-γ-亚麻酸(20:3n-6)与较高的风险相关(HR为1.29[95%CI为1.02–1.63]),而顺式-7-十六烯酸(16:1n-9c))和花生四烯酸(20:4n-6)与较低的风险相关(分别有HR为0.67[95%CI为0.47-0.97];HR为0.81[95%CI为0.65-1.00])。在排除出血性中风病例后,这些关联并不显著。

由此可见,该研究发现总共有2个NEFA亚类和3个单独的NEFA与卒中发生相关。其中,NEFAn-3亚类和二高-γ-亚麻酸来源于饮食,可能是总体卒中风险的潜在生物标志物。

原始出处:

Neil K. Huang,et al.Serum Nonesterified Fatty Acids and Incident Stroke: The CHS.JAHA.2021.https://www.ahajournals.org/doi/10.1161/JAHA.121.022725

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1070591, encodeId=a58710e0591f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Mon Nov 15 23:30:54 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268674, encodeId=e20112686e46a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 14 08:39:26 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069724, encodeId=44c61069e24d5, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c745708488, createdName=ms9000000504403725, createdTime=Fri Nov 12 19:40:27 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069705, encodeId=538c1069e0590, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211030/0f6fb6581f38487a96c7a7c397e4cf4f/278763044e44436bb15da52a1cc2b5ca.jpg, createdBy=1b7f5580654, createdName=青山桂, createdTime=Fri Nov 12 18:04:12 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-15 ms2000000371747721

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1070591, encodeId=a58710e0591f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Mon Nov 15 23:30:54 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268674, encodeId=e20112686e46a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 14 08:39:26 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069724, encodeId=44c61069e24d5, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c745708488, createdName=ms9000000504403725, createdTime=Fri Nov 12 19:40:27 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069705, encodeId=538c1069e0590, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211030/0f6fb6581f38487a96c7a7c397e4cf4f/278763044e44436bb15da52a1cc2b5ca.jpg, createdBy=1b7f5580654, createdName=青山桂, createdTime=Fri Nov 12 18:04:12 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-14 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1070591, encodeId=a58710e0591f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Mon Nov 15 23:30:54 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268674, encodeId=e20112686e46a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 14 08:39:26 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069724, encodeId=44c61069e24d5, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c745708488, createdName=ms9000000504403725, createdTime=Fri Nov 12 19:40:27 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069705, encodeId=538c1069e0590, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211030/0f6fb6581f38487a96c7a7c397e4cf4f/278763044e44436bb15da52a1cc2b5ca.jpg, createdBy=1b7f5580654, createdName=青山桂, createdTime=Fri Nov 12 18:04:12 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-12 ms9000000504403725

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1070591, encodeId=a58710e0591f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Mon Nov 15 23:30:54 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268674, encodeId=e20112686e46a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 14 08:39:26 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069724, encodeId=44c61069e24d5, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c745708488, createdName=ms9000000504403725, createdTime=Fri Nov 12 19:40:27 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069705, encodeId=538c1069e0590, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211030/0f6fb6581f38487a96c7a7c397e4cf4f/278763044e44436bb15da52a1cc2b5ca.jpg, createdBy=1b7f5580654, createdName=青山桂, createdTime=Fri Nov 12 18:04:12 CST 2021, time=2021-11-12, status=1, ipAttribution=)]
    2021-11-12 青山桂

    谢谢分享

    0

相关资讯

JNER:卒中后手部运动恢复过程中静息运动阈值的系统评价

中风是全世界成年人长期残疾的主要原因。因此,中风幸存者的康复和优化护理具有高度的社会经济优先地位。运动障碍是中风后最常见的临床缺陷,其恢复通常不完全。脑血管事件发生六个月后,60%至70%的中风幸存者

NEJM:卒中患者血管内治疗前静脉注射阿替普酶的疗效

在这项涉及欧洲患者的随机试验中,就卒中后90天的残疾结局而言,单独的EVT既不优于也不劣于静脉阿替普酶治疗后再进行EVT。两组症状性脑出血的发生率相似。

Nature子刊:癌症幸存者血脂四项出现这些变化,小心心梗和卒中!

Scientifc Reports:既往癌症和随后心肌梗死或中风患者的脂质谱和预后

Lancet子刊50万人研究:缺维生素D要补足!冠心病、卒中、全因死亡风险齐降低!

Lancet Diabetes and Endocrinology:估计维生素D与冠心病、中风和全因死亡率的剂量-反应关系:观察性和孟德尔随机分析

Stroke : 卒中患者,出院后,他们康复如何?

该研究的重要意义提供了一套基于专家共识的关键因素,在确定脑卒中患者出院后护理的地点时需要考虑

OMCL:卒中前应用二甲双胍对2型糖尿病脑出血患者1年预后的影响

二甲双胍是治疗2型糖尿病的一线药物。它可以预防糖尿病并发症。最近的研究已经证实二甲双胍具有抗氧化作用。